XML 35 R23.htm IDEA: XBRL DOCUMENT
v3.25.3

Fair Value Measurements (Tables) | 9 Months Ended
--- | ---
Sep. 30, 2025
Fair Value Measurements |
Schedule of Assets/Liabilities Measured at Fair Value on Recurring Basis | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Fair Value Measurement at September 30, 2025 and December 31, 2024
​ | ​ | (in thousands)
​ | ​ | Quoted Price in Active | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Market for Identical | ​ | Significant Other | Significant | ​ | ​ | ​ | ​
​ | ​ | Instruments | ​ | Observable Inputs | Unobservable Inputs | ​ | ​ | ​ | ​
​ | ​ | Level 1 | ​ | Level 2 | Level 3 | ​ | Total
​ | ​ | 2025 | ​ |  | 2024 | ​ |  | 2025 |  | 2024 |  | 2025 |  | 2024 |  | 2025 |  | 2024
Assets | ​ | ​ |  | ​ | ​ |  | ​ | ​ |  | ​ |  | ​ |  | ​ |  | ​ |  | ​ |
Cash and cash equivalents | ​ | $ | 1,659 | (1) | $ | 2,020 | (1) | $ | 20,288 | $ | 24,614 | $ | — | $ | — | $ | 21,947 | $ | 26,634
Processa common shares | ​ | $ | 1 | (2) | $ | 2 | (2) | $ | — | $ | — | $ | — | $ | — | $ | 1 | $ | 2
​
(1) | The Company held approximately $1,659 in cash accounts as of September 30, 2025, of which approximately $440 was held in foreign currencies (translated into U.S. dollars). As of December 31, 2024, the Company held approximately $2,020 in cash of which approximately $363 was in foreign currencies (translated into U.S. dollars).
(2) | The Company holds 51 unrestricted common shares of Processa Pharmaceuticals, Inc. (NASDAQ:PCSA), which it received as part of a royalty arrangement in 2020.

X
- References No definition available. + Details
Name: | us-gaap_FairValueDisclosuresAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3). + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details
Name: | us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration